Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants
Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects
Sponsor: AqueSys, Inc.
Listed as NCT02006693, this PHASE4 trial focuses on Primary Open Angle Glaucoma and remains completed. Sponsored by AqueSys, Inc., it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
May 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Aug 2018 — May 2019 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AqueSys, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Birmingham, United Kingdom , Bochum, Germany , Caracas, Venezuela , Frankfurt, Germany , Geneva, Switzerland , Graz, Austria , Leuven, Belgium , London, United Kingdom , Madrid, Spain , Maidstone, United Kingdom and 9 more locations